Clinical experience of Berlitione use in liver diseases
In a study including 52 patients assessed the Berlition ® 300 (“Berlin-Chemie AG/Menarini Group” company, Germany) efficacy in the treatment of chronic liver diseases. The results of treatment confirm the positive effect of the drug Berlition ® on the functional state of the liver in patients with chronic lesions of different etiology, which was seen as significant improvement in clinical condition, the normalization of the functional "hepatic indices”, decrease of cholesterol and glucose levels, significant improvement of quality of life in patients. Only one patient had moderate changes in some biochemical parameters after treatment.

Keywords: alpha-lipoic acid, Gilbert's syndrome, viral hepatitis, steatohepatitis, hepatic steatosis, drug liver damage, non-alcoholic fatty liver disease